Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.55% | -3.98% | -12.67% | -28.54% | -71.06% |
| Total Depreciation and Amortization | 23.92% | 28.51% | 5.14% | 8.62% | 13.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.10% | -2.43% | -1.52% | 19.23% | 172.80% |
| Change in Net Operating Assets | -96.61% | -138.86% | -96.77% | -79.48% | 886.29% |
| Cash from Operations | -20.23% | -20.14% | -21.74% | -36.89% | -13.54% |
| Capital Expenditure | -106.74% | -476.47% | -20.82% | 53.58% | 53.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -99.25% | -476.47% | -20.82% | 53.58% | 53.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -53.02% | -53.33% | -53.29% | -52.96% | 185,229.09% |
| Repurchase of Common Stock | -- | 54.77% | 54.77% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -52.58% | -53.32% | -53.28% | -53.91% | 183,483.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.35% | -121.48% | -116.35% | -118.52% | 204.87% |